| 000 | 01633 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514075132.0 | ||
| 264 | 0 | _c20040206 | |
| 008 | 200402s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1046/j.0306-5251.2003.01862.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBidstrup, Tanja Busk | |
| 245 | 0 | 0 |
_aCYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cSep 2003 |
||
| 300 |
_a305-14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aCarbamates _xmetabolism |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C8 |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xphysiology |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xmetabolism |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xenzymology |
| 650 | 0 | 4 |
_aPiperidines _xmetabolism |
| 700 | 1 | _aBjørnsdottir, Inga | |
| 700 | 1 | _aSidelmann, Ulla Grove | |
| 700 | 1 | _aThomsen, Mikael Søndergård | |
| 700 | 1 | _aHansen, Kristian Tage | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 56 _gno. 3 _gp. 305-14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.0306-5251.2003.01862.x _zAvailable from publisher's website |
| 999 |
_c12692354 _d12692354 |
||